Nasdaq greenlights Canary's Injective ETF, complete with staking rewards
Nasdaq has approved the listing of Canary Capital's Injective ETF, and it comes with staking rewards baked in. The nod landed in a packed news cycle that also saw Coinbase roll out institutional options and perps on Prime. Money is moving on multiple fronts — and regulators are watching.
Nasdaq cleared the listing of Canary Capital's Injective ETF, and the product carries staking rewards, according to Cointelegraph's daily roundup. That makes it one of the few exchange-traded vehicles tied to a proof-of-stake asset that also passes yield back to holders. Approval is one thing; the real test is whether institutional allocators show up.
Coinbase used the same news cycle to switch on regulated global options and perpetual futures on Coinbase Prime. The offering targets institutions in the US and other eligible regions, pushing the exchange deeper into derivatives territory that has long belonged to offshore venues.
Security is where the money is flowing. Binance's $6.3B hack has pushed fresh capital toward onchain threat prevention, with Blockaid reportedly locking in $40M in commitments, per Axios. Breaches have a way of becoming budgets.
On the tokenization front, Canton Strategic Holdings' $CNTN became the first tokenized US stock to trade under the SEC's Innovation Exemption. Meanwhile, House Democrats are weighing a broader market structure bill that would hand the SEC more oversight, shrink the CFTC's role and restrict crypto activity by federal officials, according to Eleanor Terrett.
Payments giant Stripe now lets US businesses fire off stablecoin payouts in OUSD or USDC to crypto wallets across more than 160 markets, with transfers usually landing in minutes. And politics left a mark on price action: Trump-linked tokens led crypto losses after Democrats swept the US midterm elections.
TopicsNasdaq · Canary Capital · Injective · Coinbase · Blockaid · Canton Strategic Holdings · Stripe · Binance
Source: x.com
Written by Paparazzi with AI. Not financial advice.

